Janssen to pay $15.5 million in Kentucky Risperdal case
Posted on Saturday, January 2nd, 2016 at 11:01 am by Williams Hart | Updated: Thursday, June 27th, 2019 at 2:54 pm
Kentucky New Era reported that Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, agreed to a $15.5 million settlement on December 22. The case was a consumer protection lawsuit in Kentucky that accused Johnson & Johnson of falsely marketing the second-generation antipsychotic prescription drug Risperdal.
The Kentucky Consumer Protection lawsuit stated that the manufacturer of the antipsychotic drug did not inform consumers of its dangers and that the drug was marketed for purposes other than those ordered by the U.S. Food and Drug Administration. Attorney General Conway said, “Janssen and Johnson & Johnson put patients at risk when they marketed Risperdal without disclosing the drug’s known side effects.”
According to reports, Janssen is not allowed to promote Risperdal for purposes not approved by the FDA or for populations in which it is not approved. Kentucky required Janssen to openly discuss the risks of the drug in advertisements.
Risperdal spawned male breast growth lawsuits all over the country, and there are still many cases on trial. If you have suffered any adverse side effects while taking Risperdal, contact our lawyers at Williams Hart by calling (713) 352-7071 today to learn how we can help you.